Jun 08, 2023 9:00am EDT Journal of the American Academy of Dermatology Publishes Positive DMT310 Phase 2b Acne Results
May 26, 2023 4:00pm EDT Dermata Therapeutics Announces Closing of $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
May 24, 2023 8:00am EDT Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
May 11, 2023 4:05pm EDT Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
Apr 20, 2023 6:00am EDT Dermata Announces Receipt of Type C Meeting Response from the FDA and Submission of DMT310 End of Phase 2 Meeting Package
Feb 21, 2023 4:05pm EST Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results
Dec 05, 2022 8:30am EST Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea
Nov 10, 2022 5:20pm EST Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
